In a recent study (Dutch Childhood Oncology Group [DCOG] ALL11) reported in the Journal of Clinical Oncology, Pieters et al found that modifications in therapy appeared to improve outcomes and reduce drug exposure in pediatric patients with IKZF1-deleted acute lymphoblastic leukemia (ALL) compared with treatment in the prior DCOG ALL10 study.
